
SPRB Stock Forecast & Price Target
SPRB Analyst Ratings
Bulls say
Spruce Biosciences Inc is positioned favorably within the rare endocrine disorder market, particularly with its product candidate TA-ERT for Mucopolysaccharidosis Type IIIB (MPS IIIB), which has the potential for substantial market impact due to its differentiated mechanism of action and favorable dosing schedule. The company has secured up to $50 million in funding from Avenue Capital, contingent on achieving key regulatory milestones, which provides financial stability and the potential to support the development and launch of its therapies. Recent advancements in early diagnosis and increased awareness of MPS disorders, combined with the success of enzyme replacement therapies (ERTs) for similar conditions, further bolster the positive outlook for Spruce Biosciences's market positioning and revenue potential.
Bears say
Spruce Biosciences Inc is a late-stage biopharmaceutical company that has yet to commercialize any products, creating a significant financial risk as it continues to incur net losses, which are expected to persist at least until the potential commercialization of its product candidate, TA-ERT. Recent feedback from the FDA has raised questions regarding TA-ERT's approval path, while there are concerns related to slower-than-anticipated commercial uptake due to competition and market factors, alongside medium-term dilution risks. Moreover, the company must invest in building out the necessary infrastructure to effectively launch and market its therapeutic, further complicating its financial outlook amidst ongoing operational losses.
This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares